Public Sector Pension Investment Board Purchases 19,523 Shares of Omnicell, Inc. $OMCL

Public Sector Pension Investment Board boosted its position in Omnicell, Inc. (NASDAQ:OMCL) by 12.2% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 179,181 shares of the company’s stock after purchasing an additional 19,523 shares during the quarter. Public Sector Pension Investment Board’s holdings in Omnicell were worth $5,456,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. AQR Capital Management LLC boosted its position in shares of Omnicell by 42.1% in the first quarter. AQR Capital Management LLC now owns 17,936 shares of the company’s stock valued at $627,000 after acquiring an additional 5,311 shares during the period. Empowered Funds LLC raised its stake in Omnicell by 14.3% in the 1st quarter. Empowered Funds LLC now owns 9,953 shares of the company’s stock worth $348,000 after purchasing an additional 1,243 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in Omnicell by 4.1% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 124,047 shares of the company’s stock valued at $4,337,000 after purchasing an additional 4,866 shares during the period. Jane Street Group LLC grew its position in shares of Omnicell by 201.5% during the 1st quarter. Jane Street Group LLC now owns 163,664 shares of the company’s stock worth $5,722,000 after purchasing an additional 109,382 shares in the last quarter. Finally, Mutual of America Capital Management LLC grew its position in shares of Omnicell by 4.7% during the 2nd quarter. Mutual of America Capital Management LLC now owns 125,286 shares of the company’s stock worth $3,683,000 after purchasing an additional 5,585 shares in the last quarter. 97.70% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Omnicell

In related news, EVP Corey J. Manley sold 6,106 shares of the company’s stock in a transaction that occurred on Thursday, January 8th. The shares were sold at an average price of $49.90, for a total transaction of $304,689.40. Following the completion of the transaction, the executive vice president directly owned 91,674 shares in the company, valued at $4,574,532.60. This represents a 6.24% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 2.52% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on OMCL. Piper Sandler reiterated an “overweight” rating and issued a $49.00 price target (down from $63.00) on shares of Omnicell in a research note on Friday, February 6th. Bank of America upgraded Omnicell from a “neutral” rating to a “buy” rating and set a $70.00 target price for the company in a research report on Wednesday, February 4th. Weiss Ratings raised Omnicell from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, February 9th. KeyCorp raised Omnicell from a “sector weight” rating to an “overweight” rating and set a $60.00 price target for the company in a research note on Wednesday, January 7th. Finally, Wall Street Zen cut shares of Omnicell from a “buy” rating to a “hold” rating in a research report on Saturday, February 7th. Five research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Omnicell presently has an average rating of “Moderate Buy” and an average target price of $54.50.

Omnicell Price Performance

Omnicell stock opened at $38.63 on Friday. The company has a debt-to-equity ratio of 0.14, a quick ratio of 1.22 and a current ratio of 1.43. Omnicell, Inc. has a 52 week low of $22.66 and a 52 week high of $55.00. The stock has a market capitalization of $1.73 billion, a P/E ratio of 965.99, a price-to-earnings-growth ratio of 1.42 and a beta of 0.78. The stock has a fifty day moving average of $45.57 and a 200-day moving average of $37.51.

Omnicell (NASDAQ:OMCL) last released its quarterly earnings data on Thursday, February 5th. The company reported $0.40 earnings per share for the quarter, missing the consensus estimate of $0.47 by ($0.07). The business had revenue of $313.98 million during the quarter, compared to analyst estimates of $313.36 million. Omnicell had a net margin of 0.17% and a return on equity of 3.00%. The business’s quarterly revenue was up 2.3% compared to the same quarter last year. During the same period last year, the business earned $0.60 earnings per share. Omnicell has set its Q1 2026 guidance at 0.260-0.360 EPS and its FY 2026 guidance at 1.650-1.850 EPS. On average, sell-side analysts expect that Omnicell, Inc. will post 1.09 earnings per share for the current fiscal year.

Omnicell Company Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.